MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet faces the development of acquired resistance as the major obstacle to long-term disease remission in the clinic. MET (or c-MET ) gene a...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology Vol. 12; no. 1; pp. 63 - 11
Main Authors:	Wang, Qiming, Yang, Sen, Wang, Kai, Sun, Shi-Yong
Format:	Journal Article
Language:	English
Published:	London BioMed Central 21.06.2019 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Acrylamides - pharmacology Acrylamides - therapeutic use Aniline Compounds - pharmacology Aniline Compounds - therapeutic use Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Development and progression Drug Resistance, Neoplasm Drug therapy Emerging agents and regimens for cancer therapy Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Gene amplification Gene expression Genetic aspects Hematology Humans Immunotherapy Kinases Ligands Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - genetics Medicine Medicine & Public Health MEK inhibitors Molecular Targeted Therapy Mutation Non-small cell lung carcinoma Oncology Phosphorylation Physiological aspects Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proteins Proto-Oncogene Proteins c-met - antagonists & inhibitors Proto-Oncogene Proteins c-met - genetics Remission Review Targeted cancer therapy China
ISSN:	1756-8722, 1756-8722
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!